Heterodimerization of two pathological mutants enhances the activity of human phosphomannomutase2

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Andreotti, Giuseppina ^a   Monti, Maria Chiara ^b   Citro, Valentina ^c   Cubellis, Maria Vittoria ^c  

^a CNR   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 1,6 BISPHOSPHATE; HETERODIMER; MUTANT PROTEIN; PHOMANNOMUTASE2; PHOSPHOMANNOMUTASE; PROTEIN F119L; PROTEIN R141H; UNCLASSIFIED DRUG; GLUCOSE 6 PHOSPHATE; GLUCOSE-1,6-BISPHOSPHATE; MUTASE; PHOSPHOMANNOMUTASE 2, HUMAN;

ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; ALLELE; ANALOGS AND DERIVATIVES; CHEMISTRY; CONGENITAL DISORDER OF GLYCOSYLATION; GENETICS; GLYCOSYLATION; HETEROZYGOTE; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN QUATERNARY STRUCTURE;

ALLELES; CONGENITAL DISORDERS OF GLYCOSYLATION; DIMERIZATION; GLUCOSE-6-PHOSPHATE; GLYCOSYLATION; HETEROZYGOTE; HUMANS; MUTATION; PHOSPHORYLATION; PHOSPHOTRANSFERASES (PHOSPHOMUTASES); PROTEIN STRUCTURE, QUATERNARY;

EID: 84949465374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139882     Document Type: Article

References (26)

1. Pirard M, Achouri Y, Collet JF, Schollen E, Matthijs G, Van Schaftingen E. Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes. Biochem J. 1999; 339 (Pt 1):201-7. PMID: 10085245.
2. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007; 372(3):774-97. PMID: 17681537.
3. Andreotti G, Pedone E, Giordano A, Cubellis MV. Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation. Mol Genet Genomic Med. 2013; 1(1):32-44. doi: 10.1002/mgg3.3 PMID: 24498599
4. HGMD. HGMD: http://www.hgmd.cf.ac.uk/ac/index.php. 2011. 1954227.
5. Schollen E, Kjaergaard S, Legius E, Schwartz M, Matthijs G. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet. 2000; 8(5):367-71. PMID: 10854097.
6. Andreotti G, Cabeza de Vaca I, Poziello A, Monti MC, Guallar V, Cubellis MV. Conformational Response to Ligand Binding in Phosphomannomutase2: INSIGHTS INTO INBORN GLYCOSYLATION DISORDER. J Biol Chem. 2014; 289(50):34900-10. Epub 2014/10/18. doi: 10.1074/jbc.M114.586362 M114.586362 [pii]. PMID: 25324542; PubMed Central PMCID: PMC4263888.
7. Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet. 1998; 62(3):542-50. PMID: 9497260.
8. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001; 29(1):308-11. Epub 2000/01/11. PMID: 11125122; PubMed Central PMCID: PMC29783.
9. Pirard M, Matthijs G, Heykants L, Schollen E, Grunewald S, Jaeken J, et al. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS letters. 1999; 452(3):319-22. Epub 1999/07/01. S0014-5793(99)00673-0 [pii]. PMID: 10386614.
10. Le Bizec C, Vuillaumier-Barrot S, Barnier A, Dupre T, Durand G, Seta N. A new insight into PMM2 mutations in the French population. Hum Mutat. 2005; 25(5):504-5. Epub 2005/04/22. doi: 10.1002/humu.9336 PMID: 15844218.
11. Kjaergaard S, Skovby F, Schwartz M. Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli. Eur J Hum Genet. 1999; 7(8):884-8. Epub 1999/12/22. doi: 10.1038/sj.ejhg.5200398 PMID: 10602363.
12. Vega AI, Perez-Cerda C, Abia D, Gamez A, Briones P, Artuch R, et al. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis. 2011; 34(4):929-39. Epub 2011/05/05. doi: 10.1007/s10545-011-9328-2 PMID: 21541725.
13. Yuste-Checa P, Gamez A, Brasil S, Desviat LR, Ugarte M, Perez-Cerda C, et al. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein. Hum Mutat. 2015; 36(9):851-60. Epub 2015/05/28. doi: 10.1002/humu.22817 PMID: 26014514.
14. Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, et al. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet. 1997; 16(1):88-92. PMID: 9140401.
15. Matthijs G. Congenital disorders of glycosylation. Trends in biochemical sciences. 2000; 25(9):428. PMID: 10973055.
16. Kjaergaard S, Skovby F, Schwartz M. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet. 1998; 6 (4):331-6. Epub 1998/10/22. doi: 10.1038/sj.ejhg.5200194 PMID: 9781039.
17. Bjursell C, Wahlstrom J, Berg K, Stibler H, Kristiansson B, Matthijs G, et al. Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families. Eur J Hum Genet. 1998; 6(6):603-11. Epub 1999/01/15. doi: 10.1038/sj.ejhg. 5200234 PMID: 9887379.
18. Pirard M, Collet JF, Matthijs G, Van Schaftingen E. Comparison of PMM1 with the phosphomannomutases expressed in rat liver and in human cells. FEBS letters. 1997; 411(2-3):251-4. PMID: 9271215.
19. Van Schaftingen E, Jaeken J. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS letters. 1995; 377(3):318-20. Epub 1995/12/27. 0014-5793(95) 01357-1 [pii] doi: 10.1016/0014-5793(95)01357-1 PMID: 8549746.
20. Chakraborty S, Nunez D, Hu SY, Domingo MP, Pardo J, Karmenyan A, et al. FRET based quantification and screening technology platform for the interactions of leukocyte function-associated antigen-1 (LFA-1) with intercellular adhesion molecule-1 (ICAM-1). PloS one. 2014; 9(7):e102572. Epub 2014/07/18. doi: 10.1371/journal.pone.0102572 PONE-D-14-15911 [pii]. PMID: 25032811; PubMed Central PMCID: PMC4102529.
21. Song Y, Rodgers VG, Schultz JS, Liao J. Protein interaction affinity determination by quantitative FRET technology. Biotechnol Bioeng. 2012; 109(11):2875-83. Epub 2012/06/20. doi: 10.1002/bit.24564 PMID: 22711490.
22. Andreotti G, Monticelli M, Cubellis MV. Looking for protein stabilizing drugs with thermal shift assay. Drug Test Anal. 2015. Epub 2015/04/08. doi: 10.1002/dta.1798 PMID: 25845367.
23. Arnone MI, Birolo L, Giamberini M, Cubellis MV, Nitti G, Sannia G, et al. Limited proteolysis as a probe of conformational changes in aspartate aminotransferase from Sulfolobus solfataricus. Eur J Biochem. 1992; 204(3):1183-9. PMID: 1551394.
24. Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012; 7:91. PMID: 23176611. doi: 10.1186/1750-1172-7-91
25. Zimran A, Altarescu G, Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis. 2013; 50(2):134-7. Epub 2012/10/23. doi: 10.1016/j.bcmd. 2012.09.006 S1079-9796(12)00184-2 [pii]. PMID: 23085429.
26. Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013; 51(2):116-24. Epub 2013/05/21. doi: 10.1016/j.bcmd.2013.04.005 S1079-9796(13) 00085-5 [pii]. PMID: 23683771.